JP2024518804A5 - - Google Patents

Info

Publication number
JP2024518804A5
JP2024518804A5 JP2023571825A JP2023571825A JP2024518804A5 JP 2024518804 A5 JP2024518804 A5 JP 2024518804A5 JP 2023571825 A JP2023571825 A JP 2023571825A JP 2023571825 A JP2023571825 A JP 2023571825A JP 2024518804 A5 JP2024518804 A5 JP 2024518804A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023571825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518804A (ja
JP7869816B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030400 external-priority patent/WO2022246298A1/en
Publication of JP2024518804A publication Critical patent/JP2024518804A/ja
Publication of JP2024518804A5 publication Critical patent/JP2024518804A5/ja
Application granted granted Critical
Publication of JP7869816B2 publication Critical patent/JP7869816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023571825A 2021-05-21 2022-05-20 間質性膀胱炎／膀胱痛症候群を処置する方法 Active JP7869816B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163191536P 2021-05-21 2021-05-21
US63/191,536 2021-05-21
PCT/US2022/030400 WO2022246298A1 (en) 2021-05-21 2022-05-20 Methods of treating interstitial cystitis/bladder pain syndrome

Publications (3)

Publication Number Publication Date
JP2024518804A JP2024518804A (ja) 2024-05-02
JP2024518804A5 true JP2024518804A5 (enExample) 2025-05-16
JP7869816B2 JP7869816B2 (ja) 2026-06-03

Family

ID=84140895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571825A Active JP7869816B2 (ja) 2021-05-21 2022-05-20 間質性膀胱炎／膀胱痛症候群を処置する方法

Country Status (11)

Country Link
US (1) US20240269133A1 (enExample)
EP (1) EP4340837A4 (enExample)
JP (1) JP7869816B2 (enExample)
KR (1) KR20240012516A (enExample)
CN (1) CN117750958A (enExample)
AU (1) AU2022276010A1 (enExample)
BR (1) BR112023023702A2 (enExample)
CA (1) CA3219412A1 (enExample)
IL (1) IL308315A (enExample)
MX (1) MX2023013514A (enExample)
WO (1) WO2022246298A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119421705A (zh) * 2022-06-24 2025-02-11 普渡制药公司 治疗或预防膀胱过度活动综合征的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
WO2005117862A1 (en) * 2004-06-03 2005-12-15 Pfizer Limited, Treatment of urinary conditions including incontinence
EP1676843A1 (en) 2004-12-31 2006-07-05 Nikem Research S.R.L. Substituted indole ligands for the ORL-1 receptor
CA2611030A1 (en) 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists
CA2664315C (en) 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP2254556A2 (en) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
RS52590B2 (sr) 2008-07-21 2018-05-31 Purdue Pharma Lp Jedinjenja tipa supstituisanog hinoksalina sa premošćenim piperidinom i njihova upotreba
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US9040533B2 (en) * 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
MX2020007817A (es) 2018-01-24 2020-09-25 Purdue Pharma Lp Prevención y tratamiento del trastorno del sueño.
EP3917621A1 (en) 2019-01-31 2021-12-08 Purdue Pharma LP Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound

Similar Documents

Publication Publication Date Title
JP2023002662A5 (enExample)
JP2022191257A5 (enExample)
NZ565840A (en) Therapy for the treatment of disease
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2023500060A5 (enExample)
JP2025508359A5 (enExample)
US6855735B2 (en) Ketamine treatment of restless legs syndrome
JP2023548429A5 (enExample)
CN1917874A (zh) 使用唑尼沙胺治疗和诊断睡眠障碍性呼吸的方法以及进行这种方法的装置
JP2023553253A5 (enExample)
JP2022524576A5 (enExample)
JP4370169B2 (ja) 勃起障害の治療のためのアルカノイルｌ−カルニチンの使用
JP2025503015A5 (enExample)
JP2024532957A5 (enExample)
EP1051162B1 (en) Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
JP6454436B1 (ja) ペマフィブラートを含有する医薬
JP2021530568A5 (enExample)
JP2024084670A5 (enExample)
WO2004017973A1 (ja) 統合失調症治療剤
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
IL308315A (en) Methods of treating interstitial cystitis/bladder pain syndrome
JP2008523143A (ja) 月経困難症の治療のためのα−アドレナリン遮断剤の使用
JP2025522146A5 (enExample)
JP2000219626A (ja) ケロイドおよび／または肥厚性瘢痕の治療剤
RU2071773C1 (ru) Лекарственное средство для лечения синдромов приобретенного иммунодефицита, в том числе вич-обусловленных